Sign in

You're signed outSign in or to get full access.

RI

ReposiTrak, Inc. (TRAK)·Q2 2025 Earnings Summary

Executive Summary

  • Q2 FY2025 revenue was $5.49M (+7% YoY) and diluted EPS was $0.08; GAAP net income was $1.55M (+7% YoY) and operating income was $1.35M (+9% YoY) .
  • Deferred revenue rose 70% since June to $4.16M, implying ~$1.7M incremental subscription revenue over the next 12 months and raising confidence in double-digit top-line growth into FY2026 .
  • Cash and equivalents reached $28.0M with no bank debt; capital returns continued via $0.01815 quarterly dividend, preferred redemptions, and modest buybacks .
  • Management reiterated an annual revenue growth goal of 10%–20% and cited onboarding acceleration, network effects, and cross-selling as catalysts; Wall Street S&P Global consensus data was unavailable for direct beat/miss comparison during this session .

What Went Well and What Went Wrong

What Went Well

  • “Deferred revenue has grown 70%, from $2.4 million to $4.2 million…These customers will add $1.7 million of incremental subscription revenue over the next 12 months” – CFO John Merrill, highlighting embedded growth visibility .
  • “We continue to convert higher revenues into greater profitability and cash generation, ending the quarter with record cash balances even as we return robust capital to shareholders” – CEO Randy Fields, underscoring operating leverage and capital discipline .
  • “Retailers are demanding that all food be traced, far exceeding the FDA mandates…we’re positioned as the universal translator…opening a very large additional market” – CEO on market-driven adoption and partnership strategy (e.g., Upshop) .

What Went Wrong

  • Operating expenses rose 7% YoY to $4.14M, including +15% sales and marketing tied to traceability awareness and higher commissions, compressing near-term contribution margins .
  • Cost of revenue increased (+3% YoY) from developer investments to expand the automation “Wizard,” delaying margin mix-shift toward targets near term .
  • Macro uncertainty (tariffs) and sector-specific shocks (egg supply disruptions) present external headwinds; management does not expect material impact but acknowledges potential near-term friction .

Financial Results

Consolidated Quarterly Metrics

MetricQ4 2024Q1 2025Q2 2025
Revenue ($USD)$5,200,000 $5,441,142 $5,490,908
Total Operating Expense ($USD)$3,900,000 $3,961,081 $4,138,857
Income from Operations ($USD)$1,300,000 $1,480,061 $1,352,051
GAAP Net Income ($USD)$1,600,000 $1,665,155 $1,551,080
Net Income to Common ($USD)$1,500,000 $1,557,273 $1,455,464
Diluted EPS ($USD)$0.08 $0.08 $0.08
Cash & Equivalents ($USD)$25,153,862 $25,790,206 $28,041,398
Deferred Revenue ($USD)$2,441,234 $2,585,019 $4,160,207

YoY Comparison – Q2 FY2025 vs Q2 FY2024

MetricQ2 2024Q2 2025YoY Change
Revenue ($USD)$5,125,751 $5,490,908 +7.1%
Diluted EPS ($USD)$0.07 $0.08 +$0.01
GAAP Net Income ($USD)$1,451,149 $1,551,080 +6.9%
Income from Operations ($USD)$1,240,851 $1,352,051 +9%

Versus Wall Street Estimates (S&P Global)

MetricConsensus (S&P Global)ActualResult
Revenue ($USD)N/A – SPGI consensus unavailable at time of request$5,490,908 N/A
Diluted EPS ($USD)N/A – SPGI consensus unavailable at time of request$0.08 N/A
Note: S&P Global consensus values were unavailable during this session.

Recurring Revenue Mix and Setup Fees

MetricQ1 2025Q2 2025Q3 2025 (context)
Recurring Revenue ($USD)Just under $5.4M $5.4M (+5% YoY) $5.8M (+15% YoY)
% of Total Revenue98% 98% (down from 99% due to setup fees) 98%

KPIs and Operating Cash Flow

KPIQ4 2024Q1 2025Q2 2025
Deferred Revenue ($USD)$2,441,234 $2,585,019 $4,160,207
Operating Cash Flow ($USD)FY2024: $6,964,401 $1,868,900 (quarter) $5,328,630 (six months YTD)
Facilities in Onboarding Pipeline~5,000 (with 4,000 companies) —~5,500 facilities
Wizard Automation Adoption——~70% of new suppliers via Wizard (Q3 context)

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Revenue Growth (YoY)FY2025“Double-digit” for balance of FY25 and into FY26 10%–20% annual top-line growth target reiterated Clarified range
DividendOngoingIncreased to $0.01815/quarter starting Dec 2024 $0.01815/quarter; paid within 45 days of quarter-end Maintained rate, timing affirmed
Capital AllocationOngoingRedeem preferred (~$750K/quarter), 50% of op cash to shareholders Same cadence; buybacks opportunistic; no bank debt Maintained
FSMA 204 TimingIndustry AdoptionAdvocated for enforcement delay; retailers pushing “trace all food” Later (Q3 context): FDA extended enforcement by 30 months; adoption pace unchanged External timing relief (context)

Earnings Call Themes & Trends

TopicPrevious Mentions (Q4 2024, Q1 2025)Current Period (Q2 2025)Trend
Traceability adoptionRetailers (Kroger, Walmart, Target) requiring all food traced; pipeline ~4,000 companies/~5,000 facilities Retailers driving adoption; inevitability emphasized; suppliers onboarding accelerating Strengthening, market-led adoption
Automation/WizardOngoing investment; goal to scale automated onboarding Wizard progress; aiming 60–70% self-onboarding; ongoing dev investments Increasing automation
Deferred revenue visibilityFY2024 deferred revenue $2.44M Deferred revenue $4.16M (+70% since June); ~$1.7M incremental rev next 12 months Up sharply, supports growth
Tariffs/macroNoted broader food safety catalysts Tariffs seen as uncertainty but not a major impact Manageable macro backdrop
Partnerships—Data-agnostic “universal translator”; partnership with Upshop Expanding ecosystem
Regulatory/legal (FSMA 204)Retailers pulling timelines ahead of FDA Expect delay beneficial; law unchanged; market forces dominate Delay likely beneficial (Q3 later confirmed)
Capital allocationDividend increases; preferred redemptions; buybacks; no debt Continued preferred redemption, dividend cadence, cash build Consistent return of capital
AI/process efficiencyLong-standing internal AI use; cost discipline AI not capex heavy; annual capex < $1M Efficient, pragmatically applied

Management Commentary

  • “Since June 2024, our deferred revenue has grown 70%, from $2.4 million to $4.2 million…adds about $425,000 to each subsequent quarter” – CFO quantifying near-term revenue layering .
  • “Retailers…are demanding that all food be traced, far exceeding the FDA mandates…we’re positioned as the universal translator” – CEO on TAM expansion and platform advantage .
  • “We continue to convert higher revenues into greater profitability and cash generation…record cash balances…return robust capital to shareholders” – CEO reinforcing capital allocation discipline .
  • “It takes $12 million in cash to run this place…our goal is to deliver $0.80-plus profit on every dollar of incremental revenue” – CFO on fixed cost base and margin aspirations .

Q&A Highlights

  • Onboarding efficiency: Wizard progress “right where we hoped,” with aspiration for 60–70% self-onboarding without assistance within a year .
  • Cost structure: Fixed cash costs ~$12M; incremental variable costs mainly commissions and related taxes; similar contribution margins across traceability, compliance, and supply chain .
  • Macro: Tariffs viewed as transient uncertainty; egg shortages driven by avian flu have no practical workaround, highlighting supply-chain realities .
  • AI and capex: No change to capex due to AI (annual capex typically < $1M); AI focused on internal process efficiency vs. “bots” .
  • Capital returns: Board targets ~50% of operating cash returned to shareholders (dividends, buybacks, preferred redemption) with the remainder to cash; opportunistic adjustments each quarter .

Estimates Context

  • S&P Global consensus for Q2 FY2025 EPS and revenue was unavailable during this session; no verified beat/miss comparison can be made. Given the 70% deferred revenue increase and strong cash generation, estimate revisions may trend upward for FY2025–FY2026 revenue and EPS as onboarding converts to recognized revenue .

Key Takeaways for Investors

  • Embedded growth: Deferred revenue of $4.16M (+70% since June) supports sequential revenue layering (~$1.7M over 12 months) and strengthens visibility into double-digit growth .
  • Operating leverage intact: Despite higher near-term OpEx for automation and marketing, the fixed cost base (~$12M) and platform scale should expand margins over time .
  • Market-led adoption: Retail mandates to trace all food expand TAM beyond FSMA 204, with ReposiTrak positioned as a data-agnostic “universal translator” and partner ecosystem (e.g., Upshop) .
  • Capital allocation discipline: Dividend at $0.01815/quarter, ongoing preferred redemptions (~$750K/quarter), opportunistic buybacks, and no bank debt create shareholder-friendly cash returns .
  • Near-term trading: Watch for sequential revenue growth and ARR conversion from deferred revenue; any FDA enforcement timing updates are likely a constructive catalyst given onboarding complexity (Q3 context: 30-month extension) .
  • Medium-term thesis: Cross-selling across compliance/traceability/supply chain, automation-driven onboarding, and network effects should drive sustained 10%–20% top-line growth and faster EPS/cash generation .
  • Risk monitor: Track sales/marketing spend and developer investment cadence vs. margin trajectory; macro disruptions (e.g., tariffs, supply shocks) could affect customers’ timing even if not structurally material .